Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Assets (2017 - 2025)

Historic Current Assets for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $1.1 billion.

  • Crinetics Pharmaceuticals' Current Assets rose 2776.8% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 2776.8%. This contributed to the annual value of $1.4 billion for FY2024, which is 13955.08% up from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Current Assets of $1.1 billion as of Q3 2025, which was up 2776.8% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Current Assets peaked at $1.4 billion during Q4 2024, and registered a low of $157.8 million during Q1 2021.
  • For the 5-year period, Crinetics Pharmaceuticals' Current Assets averaged around $621.1 million, with its median value being $416.3 million (2022).
  • Its Current Assets has fluctuated over the past 5 years, first plummeted by 3158.29% in 2023, then skyrocketed by 20714.37% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Current Assets (Quarter) stood at $344.7 million in 2021, then rose by 0.13% to $345.2 million in 2022, then soared by 66.33% to $574.2 million in 2023, then skyrocketed by 139.55% to $1.4 billion in 2024, then fell by 18.48% to $1.1 billion in 2025.
  • Its last three reported values are $1.1 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.3 billion during Q1 2025.